All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

Full Title: Antiphospholipid antibodies exacerbate damage following oxygen deprivation-reperfusion injury in an in vivo model for stroke and in ex vivo blood derived endothelial cells

Short Title:

Antiphospholipid antibodies in reperfusion injury

Charis Pericleous^{1,2*}, Daniel J. Stuckey^{3‡}, Robert T. Maughan^{1‡}, Koralia Paschalaki¹, Lida Kabir¹, Lauren T. Bourke², Rohan Willis⁴, Anisur Rahman², Anna M. Randi¹, Deepa J. Arachchillage^{5,6}, Mark Lythgoe³, Ian P. Giles², Justin C. Mason^{1,6§}, Yiannis Ioannou^{2§}

¹National Heart & Lung Institute, Imperial College London, London, UK

²Centre for Rheumatology, University College London, London UK

³Centre for Advanced Biomedical Imaging, University College London, London UK

⁴Rheumatology, University of Texas Medical Branch, Galveston, TX, USA

⁵Department of Immunology & Inflammation, Imperial College London, London UK

⁶Imperial College NHS Trust, London, UK

- [‡]contributed equally
- §joint senior authors
- *Corresponding author:
- **Charis Pericleous**
- Imperial College London
- National Heart & Lung Institute ICTEM L5
- Du Cane Road, London W12 0NN
- Email: c.pericleous@imperial.ac.uk
- Tel: + 44 207 594 2728

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

52 Abstract

53

54 **Background:** Prothrombotic antiphospholipid antibodies (aPL) found in patients with 55 antiphospholipid syndrome (APS) are a recognised risk factor for ischemic stroke. However, 56 it is unclear if aPL cause injury post thrombolysis leading to worse outcomes. We investigated 57 whether aPL exacerbate reperfusion injury and sought to translate our findings in endothelial 58 colony forming cells (ECFC) isolated from patients with APS.

- 59 **Methods:** Transient ischemic stroke was induced in adult rats injected with serum-derived 60 IgG from patients with APS (APS-IgG, containing aPL) or healthy controls (HC-IgG). Infarct 61 size and intracellular signalling processes involved in ischemia-reperfusion injury were
- 62 determined post reperfusion. *In vitro*, human umbilical vein endothelial cells (HUVEC) treated 63 with IgG, as well as APS and HC ECFC, were exposed to hypoxia (0.1% O₂). Cell death and
- 64 relevant signalling mechanisms were assessed following reperfusion and compared to 65 matched normoxic cultures.
- 66 **Results:** *In vivo*, APS-IgG induced >2-fold larger infarcts and lower levels of active 67 phosphorylated Akt, a key pro-survival kinase, compared to HC-IgG. *In vitro*, aPL-mediated 68 cell death and suppression of Akt phosphorylation was confirmed in HUVEC exposed to IgG 69 and hypoxia-reperfusion. Consistent with these findings, higher rates of cell death and 70 reduced Akt phosphorylation following reperfusion were observed in *ex vivo* APS ECFC 71 compared to HC ECFC. Treatment with the immunomodulating agent hydroxychloroquine 72 ampliorated ECFC death and this effect was more pronounced in APS derived cells
- ameliorated ECFC death and this effect was more pronounced in APS-derived cells.
- Conclusion: Patient-derived IgG aPL exacerbate cell death following reperfusion in a novel
 in vivo stroke model for APS, as well as *in vitro* HUVEC cultures. These observations are
 mimicked in *ex vivo* APS ECFC. Our findings describe a novel pathogenic role for aPL in
- 75 mimicked in *ex vivo* APS ECFC. Our findings describe a novel pathogenic role for aPL in 76 mediating tissue injury in addition to their known thrombogenic properties and indicate
- 77 potential for pharmacological intervention.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

78 Introduction

79

80 Stroke remains a significant cause of morbidity and mortality worldwide. Ischemic stroke 81 accounts for >80% of cases and 10-15% of those occur in young adults.¹ Approximately 10-82 20% of patients under 50 years old with stroke have antiphospholipid syndrome (APS), the 83 most common identifiable cause of acquired hypercoagulability in the general population.^{2,3} 84 APS is clinically defined by thrombotic events and/or obstetric complications with persistent 85 presence of circulating antiphospholipid autoantibodies (aPL).⁴ aPL positivity is a strong risk 86 factor for stroke, particularly in young patients and in the absence of classical cardiovascular 87 risk factors (e.g. hyperlipidemia, hypertension, smoking, metabolic disease). Risk of recurrent 88 thrombosis is also elevated in aPL-positive young patients. A prospective study of >1800 89 patients between 18-45 years old and previous ischemic stroke identified aPL as an 90 independent predictor of long-term recurrent vascular events after first stroke using a 91 composite endpoint of stroke, transient ischemic attack, myocardial infarction (MI) or other 92 arterial events.5

93

94 Pathogenic aPL are primarily raised against plasma cofactors that bind phospholipids; more 95 recently pathogenic aPL that directly target phospholipids have also been described.⁶ To date 96 the plasma protein beta-2 glycoprotein I (β 2GPI) has been identified as the most important 97 autoantigen. The ability of β 2GPI to bind cell membrane receptors and phospholipids 98 facilitates aPL priming of endothelium, platelets, monocytes and neutrophils resulting in a 99 proinflammatory and procoagulant phenotype.⁷ Thrombosis in APS is a 'two-hit' phenomenon: 100 aPL provide the first thrombophilic 'hit' and clotting ensues upon exposure to a second 'hit' 101 such as infection or injury. Endothelial injury is central to APS pathogenesis, and existing 102 animal models convincingly demonstrate the prothrombotic nature of aPL and endothelial 103 involvement in carotid, cardiac, mesenteric and femoral vascular territories.8-14

104

105 Restoration of blood flow with thrombolysis is the first-line treatment for occlusive ischemic 106 events. However, organ reperfusion can exacerbate tissue damage. The extent of reperfusion 107 injury is ultimately determined by the complex interplay between intracellular 'live-or-die' 108 signals modulated by the activity of key protein kinases. In cardiac ischemia-reperfusion injury, 109 the role of protein kinase B (PKB/Akt) and p38-mitogen activated protein kinase 110 (MAPK)/extracellular signal-regulated kinase (ERK) signalling are well established and 111 directly relate to myocardial damage.¹⁵ Similarly, these kinases are implicated in brain 112 ischemia-reperfusion injury and neuronal survival.^{16,17} aPL can regulate all three kinases.^{7,18-} 113 ²⁴ We previously demonstrated that aPL engage p38-mitogen activated protein kinase (MAPK) 114 to promote cell death in a model of hypoxia-reperfusion injury in vitro using primary rat 115 cardiomyocytes; this mechanism was dependent on the interaction between aPL and the 116 immunodominant region of β₂GPI.²⁵ In vivo, β2GPI localizes to the liver and uterus but spreads 117 to the brain when mice are challenged with lipopolysaccharide²⁶ suggesting that B2GPI 118 localizes to the brain following a pathogenic insult. Following stroke, B2GPI synthesis is 119 upregulated in the liver, localizes to the brain parenchyma and endothelium, and promotes 120 vascular inflammation.²⁷ It is therefore plausible that, following ischemia-reperfusion injury and 121 endothelial blood-brain barrier (BBB) breakdown, aPL entering the brain microcirculation can 122 interact with brain tissue via β_2 GPI.

123

124 It is unclear whether aPL increase stroke severity or impact long-term outcomes; studies in 125 patients are limited but suggest increased stroke severity and risk of post-stroke disability,28 126 impairment²⁹ and haemorrhagic transformation associated with cognitive longer 127 hospitalisation periods and higher mortality.³⁰ We hypothesized that aPL disrupt the fine 128 balance between cell survival and death post ischemia and exacerbate stroke damage during 129 reperfusion by targeting essential survival signalling mechanisms. We employed a well-130 established rat model of transient middle cerebral artery occlusion (MCAO) to design the first

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

in vivo model for stroke in APS and translated our findings in patient endothelial colony forming
 cells (ECFC), a novel source of patient-derived endothelium isolated from venous blood.³¹

133 134 <u>Methods</u>

135136 Patients and healthy donors

All research subjects signed informed consent according to the Declaration of Helsinki and
 approved by the appropriate local, regional and/or national Ethics board (University College
 London, Imperial College London, University of Texas Medical Branch).

140

A total of 20 patients with APS and 17 healthy controls (HC) were recruited for this study.
Polyclonal IgG was isolated from 14 APS and 12 HC; ECFC were isolated from 12 APS and
12 HC donors. Samples from 6 patients and 7 HC were used for both IgG and ECFC isolation.

- Demographics and clinical information are listed in Table 1. Positive aPL status was recorded
 from clinical records and confirmed for IgG anti-cardiolipin (aCL) and anti-β2GPI (aβ2GPI)
- 145 Irom clinical records and confirmed for IgG anti-cardiolipin (aCL) and 146 using in-house assays (see Methods: IgG aPL activity).
- 147

148 IgG purification

IgG was purified from human serum by protein G chromatography (ThermoFisher Scientific
UK). IgG preparations were concentrated and dialyzed in phosphate buffered saline (PBS)
and confirmed to be free of endotoxin (<0.1EU/mL at 1mg/mL concentration of IgG) (EndoLisa,
Hyglos Germany).

153

For *in vivo* experiments, equal amounts of IgG isolated from two APS patients with comparable aPL activity (Table 1) were pooled into a single sample (APS-IgG). A second IgG pool was prepared from four aPL-negative healthy controls (HC-IgG). Both pools were prepared to a concentration of 1mg/mL under sterile conditions. For *in vitro* experiments, IgG samples were tested individually at a concentration of 100µg/mL.

159

160 **IgG quantification**

161 Individual and pooled IgG samples were quantified by spectrophotometry and enzyme-linked 162 immunosorbent assay (ELISA).^{13,32} Briefly, 96-well maxisorp plates (Nunc) were coated with 163 an Fc-specific anti-human IgG antibody (Sigma-Merck UK) and blocked to minimize non-164 specific binding. Serially diluted human IgG was tested in duplicate. Goat anti-human 165 horseradish peroxidase (HRP)-conjugated IgG (Sigma-Merck), teramethybenzidine (TMB) 166 substrate and 0.1M sulphuric acid (KPL Diagnostics, Insight Biotechnology UK) were 167 employed and optical density read at 450nm. IgG concentrations were calculated from a 168 standard curve generated by serially diluting commercially sourced IgG from 100ng/mL to 169 3.125ng/mL (Sigma-Merck).

170

Human IgG content was also measured in rodent serum (1:400 dilution)^{13,32} and neat brain
tissue lysates (prepared as described below). To confirm assay specificity for human IgG,
serum and brain lysates from three rats not injected with human IgG or subjected to MCAO
were tested. No signal was detected (data not shown).

176 IgG aPL activity

177 IgG aCL and aß2GPI activity was measured in purified IgG fractions, human and rat serum 178 using direct ELISA with pre-defined cut offs as previously described.³³ In brief, 96-well plates 179 were coated with bovine cardiolipin (Sigma-Merck) or human B2GPI (Enzyme Research 180 Laboratories UK). Human serum, rodent serum and purified IgG (serially diluted from 500µg/mL) were tested as described.^{13,32} Signal detection was performed as per the total 181 182 human IgG ELISA. aCL activity was defined as IgG phospholipid units (GPLU) using validated 183 calibrators (Louisville aPL Diagnostics, USA; activity range 16-120 GPLU). For a
^β2GPI, 184 activity was defined as IgG B2GPI units (GBU) using in-house calibrators (activity range 3.1-

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

185 100 GBU). Titres >99th percentile of the activity of n=200 control sera were considered positive
 186 (17GPLU; 8GBU).³³ LA testing and interpretation was performed by the clinical laboratory
 187 following ISTH guidelines.³⁴

188 189 *In vivo* studies

190 Animal studies were approved by the University College London Biological Services Ethical 191 Review Committee and licensed under the UK Home Office regulations and the Guidance for 192 the Operation of Animals (Scientific Procedures) Act 1986 (Home Office, London, United 193 Kingdom). Male Sprague Dawley (SD) rats (Charles River, UK) weighing between 200-220g, 194 receiving a standard diet and water ad libitum were anaesthetized with 2% isoflurane and 195 injected intravenously with 1mg of pooled APS-IgG or HC-IgG (n=5 per group). The trachea 196 and common carotid artery (CCA) were exposed and isolated. Fifteen minutes post IgG 197 injection, a sterile microfilament was introduced into the CCA and positioned to fully occlude the right MCA.^{35,36} After 0.5hr or 1hr ischemia, the microfilament was removed to enable 198 199 reperfusion. Animals were allowed to recover, provided with soft tissue bedding, unrestricted 200 access to water and food and euthanized 24hr post reperfusion (endpoint).

201

209

Two additional groups of rats (n=6 per group) were injected with 1mg of APS-IgG or HC-IgG
 but not subjected to MCAO surgical procedures. Animals were maintained for 24hr post
 injection prior to sacrifice.

Immediately following sacrifice, blood was collected by cardiac puncture for serum isolation.
Selected organs were examined and collected for downstream analysis as described below.
A schematic of our model is shown in Supplementary Figure 1B.

210 Infarct size analysis

Brains isolated from rats subjected to MCAO were cut into 1mm slices and stained with tetrazolium chloride (TTC) to discriminate between metabolically active (red) and dead tissue (white). Representative slices from an APS-IgG treated rat are shown in Figure 1C. A total of 12-13 slices per animal were digitally analysed by a technician blinded to the treatment groups. The area (mm³) of viable and infarcted regions (Figure 1C, red and white tissue respectively) was measured on both sides of each slice and lesion size calculated as a percentage of total brain area.

218

219 Endothelial cell culture

Pooled human umbilical vein endothelial cells (HUVEC, Lonza) were cultured in complete
 endothelial growth medium (EGM2) containing 10% FBS. Experiments were performed at
 passage 4.

224 For ECFC generation, peripheral blood mononuclear cells (PBMC) were isolated from whole 225 blood by gradient centrifugation (Ficoll-Paque Plus GE Healthcare). Counted viable PBMC 226 were resuspended in complete EGM2 supplemented with 20% FBS and seeded at $\geq 0.8 \times 10^6$ 227 / cm² in culture vessels pre-coated with Type I rat tail collagen (BD Bioscience). The media 228 was carefully changed two days post-seeding and repeated every 2-3 days. From five days 229 post-seeding, cultures were routinely screened for the appearance of cobblestone cells that 230 formed dense endothelial colonies over time. Cultures were expanded for 6-8 weeks post-231 PBMC seeding. Our ECFC isolation protocol is summarized in Supplementary Figure 3A. 232 Representative images of an emerging colony, expanded ECFC and expression of canonical 233 endothelial markers detected by immunofluorescence, are shown in Supplementary Figure 234 3B. ECFC were confirmed to be of endothelial but not myeloid lineage by flow cytometry 235 (CD31+/CD144+/CD146+/CD45-/CD14-, Supplementary Figure 3C) and ≥98% pure at 236 passage 4. Experiments were performed at passage 4-5.

237

238 Simulated hypoxia-reperfusion *in vitro*

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

239 Hypoxia was mimicked by incubating cell cultures in 0.1% O₂/5% CO₂ supplemented with 240 nitrogen (H35 hypoxic workstation, Don Whitley Scientific) for 4hrs followed by reperfusion 241 under standard culture conditions (~20% O₂) for 0.5hr to 24hrs. Endothelial basal medium 242 (EBM2) in the absence of growth factors or FBS was used during hypoxia. Cells were switched 243 back to complete EGM2 during reperfusion. Where indicated, matched normoxic cultures were 244 kept under standard conditions in EGM2 for the duration of each experiment. Endothelial 245 cultures were routinely visualized to confirm confluency and monolayer robustness throughout 246 the outlined experimental conditions and time points. All measurements were performed in \geq 247 2 independent experiments.

248

HUVEC were pre-incubated with 100µg/mL purified human IgG for 24hr prior to hypoxiareperfusion simulation. IgG was retained in the culture medium at all times.

251

ECFC were cultured in the absence of exogenous IgG. For targeted experiments with hydroxychloroquine (HCQ, 10µg/mL), ECFC were pre-treated with the drug for 24hr prior to hypoxia-reperfusion simulation. HCQ was retained in the culture medium at all times.

256 **Protein extraction**

257 Small brain slices from the posterior part of the brain were collected from all animals (MCAO and no MCAO) and snap frozen in liquid nitrogen. The kidney, liver, spleen, left carotid artery 258 259 and aorta were also snap frozen. Tissues were ground to a fine powder using a mortar and 260 pestle placed on dry ice. Approximately 150-200µg of ground tissue was mixed with RIPA 261 (ThermoFisher) or cell lysis buffer (Cell Signaling Technologies UK) containing protease and 262 phosphatase inhibitors (Roche) and incubated on ice for 10min. Lysates were passed through 263 a glass homogeniser and incubated on ice for a further 15min, then spun at 17000g for 10min 264 to pellet cell debris. Total protein in collected supernatants was quantified by bicinchoninic 265 acid (BCA) assay (ThermoFisher) and stored at -20°C.

266

HUVEC and ECFC were placed on ice and washed twice with HBSS, incubated for 10min
with lysis buffer and manually scraped off the culture vessel. Lysates were spun, supernatant
collected and quantified as above.

271 Immunoblotting

272 10µg protein lysate was mixed with loading buffer containing SDS and dithiothreitol (DTT), 273 boiled at 95°C for 5mins, separated by electrophoresis (4-12% Bolt Bis-Tris pre-cast gels, 274 ThermoFisher) and transferred onto polyvinylidene difluoride (PDVF) membrane (GE 275 Healthcare UK). Membranes were incubated with primary antibodies followed by species-276 specific HRP-conjugated or fluorescently labelled secondary antibodies (Supplementary 277 Table 1). Proteins were visualized by chemiluminescence after substrate addition (ECL, GE 278 Healthcare) or by fluorescence (LICOR Odyssey imaging system). Molecular target levels 279 were normalised by calculating the ratio between phosphorylated and total target protein or 280 phosphorylated protein and housekeeping/loading controls. 281

282 Immunoprecipitation

100µg tissue lysate in 200µL lysis buffer was mixed with 5µL of Akt antibody and incubated
with gentle rocking overnight at 4°C. Then, 20µL of protein G agarose (ThermoFisher) was
added for a further 3hr and the mixture centrifuged at 14000g for 30sec. After five washes with
cold lysis buffer, the pellet was resuspended in SDS loading buffer and handled as described
above.

289 Endothelial cell kinetic apoptosis & necrosis assay

HUVEC or ECFC were seeded at 1x10⁴ per well in 96-well white walled clear bottom culture
 plates and tested in triplicate under hypoxia-reperfusion and normoxic conditions. Following
 2hr reperfusion, apoptosis and necrosis was simultaneously measured in hypoxia-reperfusion
 and matched normoxic plates by luminescence and fluorescence respectively (RealTime-Glo

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

Annexin V Apoptosis and Necrosis Assay, Promega UK). Luminescence and fluorescence measurements were obtained for 24hr post reperfusion and expressed as fold change of apoptosis or necrosis in hypoxia-reperfusion versus matched normoxic cells. Samples were tested in \ge 2 independent experiments.

As a positive control for this assay, HUVEC under normoxic conditions were treated for 2hr with 100 μ M hydrogen peroxide (H₂O₂) followed by washout/recovery for 24hr. H₂O₂ induced both necrosis and apoptosis (Supplementary Figure 2A). Results are expressed as fold change of apoptosis/necrosis between H₂O₂ and untreated HUVEC (n=2 individual HUVEC pools).

305 Statistical analysis

306 Results are presented as (A) Box-and-whisker plots with each data point representing an 307 individual sample. The vertical line inside each plot represents the median value for each data 308 set ± interquartile range (IQR); or (B) line graphs, each line representing an individual sample. 309 Two-tailed unpaired Mann Whitney were used to compare 2 experimental groups and 310 Kruskall-Wallis followed by Dunn's multiple comparisons tests for >2 groups. Where 311 applicable, paired analysis was performed with equivalent paired non-parametric tests. For 312 correlation analysis, Spearman's tests were applied. Significance in all cases, p<0.05. 313 Experiments with n≤3 per group were not statistically analysed.

315 Results

314

316

317 **APS-IgG increase brain infarct size**

For *in vivo* studies, purified IgG was pooled from 2 patients with APS and 4 HC (Table 1). Patients were triple aPL positive in serological assays (LA, high titre IgG aCL, IgG $a\beta_2$ GPI) and all HC were negative. Purified IgG samples were individually tested for aPL activity prior to pooling, confirming high-titre aPL activity in APS-IgG (at 100µg/mL, aCL and $a\beta_2$ GPI activity was >100 units for both samples)³³ and lack of aPL activity in HC-IgG (tested at up to 500µg/mL; Supplementary Figure 1A).

- 325 In the first instance, we performed MCAO for 1hr followed by 24hr reperfusion. Brain infarcts 326 in the APS-IgG group tended to be larger than HC-IgG. The border zone, the most peripheral 327 zone of the affected area and with less distinct pallor than the infarcted core, was also 328 extended (Figure 1A). However, three of eight animals injected with APS-IgG (37.5%) died 329 within 2hr reperfusion. Histology performed on two of three deceased rats revealed infarcts 330 >30% of total brain area (Figure 1A, red diamonds). For the remaining five APS-IgG animals 331 that survived 24hr post reperfusion plus the two histologically analysed animals that died, we 332 observed a series of systemic abnormalities during histological analysis. Specifically, we 333 identified brain clots in 4/7 animals; liver clots in 1/7; dark areas across the heart in 5/7; dark 334 areas in the lungs in 1/7; trouble breathing in 1/7; piloerection in 1/7; and viscous blood in 3/7. 335 Only one animal in the HC-IgG group had dark spots on the liver and viscous blood at 336 endpoint.
- 337
- The sudden death of a substantial proportion of APS-IgG animals combined with our histological observations suggested that experimental conditions were too harsh in the presence of aPL, and potentially resembled a phenotype closer to the clinical syndrome 'catastrophic APS.' This rare form of APS is typified by spontaneous development of multiple microthrombi, consequent multi-organ failure and 40-50% mortality despite aggressive immunosuppression. Therefore, we opted to reduce the duration of MCAO to 0.5hr and maintain reperfusion at 24hr (schematic summary, Supplementary Figure 1B).
- 345
- Under these conditions, APS-IgG animals had 2.3-fold larger infarcts compared to HC-IgG
 [infarcted % of total brain area, median (IQR) 31.3% (28.2-36.6) versus 13.6% (10.2-18.9),

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

p=0.008; n=5 per group) (Figure 1B-C)]. We singularly noted dark areas in the kidney and liver
 in two animals and a third had viscous blood. No other abnormalities or premature death were
 seen.

351

For comparison, two additional groups of animals received APS-IgG or HC-IgG but were not subjected to MCAO (no-MCAO); endpoint was defined as 24hr post-IgG transfer. In brain lysates prepared from MCAO and no-MCAO groups, human IgG was more abundant in MCAO compared to no-MCAO tissue, confirming BBB breakdown (Figure 1D). Human IgG levels were similar in APS-IgG and HC-IgG MCAO brain lysates suggesting that any downstream differences can be directly attributed to pathogenic aPL found in APS-IgG.

359 Similarly, circulating human IgG was detected in both APS-IgG and HC-IgG treated rats. 360 Human IgG levels were higher in MCAO compared to no-MCAO littermates and may point towards IgG retention in the circulation following injury (Figure 1E). In line with this, serum aPL 361 362 activity was detectable in APS-IgG treated rats 15min post-injection (Figure 1F) and at 363 endpoint (Figure 1G-H). While circulating aCL were equally detectable in both MCAO and no-364 MCAO APS-IgG littermates (Figure 1G), a³2GPI levels were pronounced in the APS-IgG 365 MCAO group only (Figure 1H) suggesting greater aß2GPI retention following injury. All HC-366 IgG rat sera were aPL negative.

368 APS-IgG inhibit pro-survival Akt following brain ischemia-reperfusion injury

369

367

- 370 Consistent with enhanced infarct size in APS-IgG animals, the apoptotic marker cleaved 371 caspase-3 was elevated in APS-IgG compared to HC-IgG animals following MCAO, and 372 minimal or absent in no-MCAO brain lysates (Figure 1I). We assessed whether aPL disrupts 373 pro-survival mechanisms, key for limiting reperfusion injury and initiating repair. 374 Phosphorylation of the pro-survival kinase Akt (p-Akt) was measured on its two critical 375 activation sites (S473, T308); T308 phosphorylation allows initial Akt activation and S473 376 phosphorylation further enhances its catalytic activity. In the absence of MCAO, p-Akt S473 377 levels were similar in APS-IgG and HC-IgG animals (Figure 2A, Supplementary Figure 1C). 378 Following MCAO and as expected, p-Akt S473 levels were higher in HC-IgG treated animals 379 compared to their no-MCAO littermates, suggesting induction of pro-survival signalling. 380 However, elevated p-Akt following MCAO was not observed in APS-IgG animals. Comparison 381 of APS-IgG and HC-IgG MCAO groups revealed strikingly lower phosphorylation at both S473 382 (Figure 2A, Supplementary Figure 1C) and T308 (Supplementary Figure 1D) in the presence of aPL. Levels of p-Akt S473 negatively correlated with infarct size highlighting the protective 383 384 role of Akt following ischemia-reperfusion injury (r= -0.9048, p=0.005; Supplementary Figure 385 1E). Phosphorylated levels of other key kinases involved in reperfusion signalling were similar
- between APS-IgG and HC-IgG animals following MCAO (p38, ERK1/2, JNK1/2;
 Supplementary Figure 1F). Taken together, our observations indicate specific inhibition of p Akt by aPL following oxygen deprivation-reperfusion.
- 390 Previous studies highlight the ability of IgG aPL to interfere with Akt signalling. Canaud et al 391 reported aPL-mediated induction of p-Akt contributing to endothelial hyperplasia in APS nephropathy²⁴ while Sacharidou et al demonstrated prothrombotic aPL-mediated inhibition via 392 393 protein phosphatase 2A (PP2A),³⁷ one of three molecular Akt inhibitors. We searched for 394 involvement of the molecular Akt inhibitors PP2A, phosphatase and tensin homolog (PTEN) 395 and thioesterase superfamily member 4 (*THEM4*, CTMP) in a limited number of brain lysates 396 from animals subjected to MCAO. Total levels of the PP2A catalytic subunit (PP2AC) and 397 PTEN did not differ between APS-IgG and HC-IgG groups (Figure 2B, left panel). CTMP was 398 not detected. Following targeted Akt immunoprecipitation, evidence favouring PP2A 399 involvement was inconclusive (Figure 2B, right panel and Figure 2C). Instead, an interaction 400 between Akt and PTEN in APS-IgG animals was detected (Figure 2B, right panel and Figure 401 2D). Akt-bound PTEN was in an activated form as shown by its dephosphorylated state (Figure 402 2B, right panel and Figure 2E). Since PTEN degradation following stroke may be

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

neuroprotective,³⁸ its role and potential manipulation in our model may warrant future 403 404 exploration.

405

406 Next, we studied the catalytic ability of Akt by measuring activation of its downstream substrates in MCAO brain lysates. Phosphorylated levels of the pro-apoptotic BCL2-407 408 associated agonist of cell death (p-Bad), which is inhibited by Akt phosphorylation on S136, 409 were reduced in APS-IgG animals (Figure 2F). Consistent with elevated cleaved caspase-3 410 levels (Figure 1H), a process also regulated by Akt, these observations highlight exacerbated 411 pro-death signalling in the presence of aPL.

412

413 Akt supports protein synthesis via phosphorylation of the mammalian target of rapamycin 414 (mTOR) and its downstream effector S6 ribosomal protein (S6RP). Lower p-S6RP levels were 415 detected in the APS-IgG group (Akt target site serine-235/6, Figure 2G). This was an intriguing 416 finding since Canaud et al demonstrated elevated p-Akt and p-S6RP localized to vascular 417 endothelium in renal biopsies from APS nephropathy patients compared to non-APS disease 418 and healthy controls.²⁴ We probed kidney lysates from our animal model and found that, in 419 stark contrast to the brain, p-Akt kidney levels were higher in APS-IgG than HC-IgG following 420 MCAO (Figure 2H, Supplementary Figure 1G). For comparison, we measured p-Akt levels in 421 the liver and spleen but did not detect any differences suggesting that in our model, aPL 422 specifically modulated p-Akt in the brain and kidney (Supplementary Figure 1H). 423

The APS nephropathy study suggested that aPL activate Akt in the absence of other stimuli.²⁴ 424 425 Upon challenge with exogenous vascular endothelial growth factor (VEGF, a potent Akt 426 inducer), aPL were shown to inhibit activation of the vascular homeostatic enzyme endothelial 427 nitric oxide synthase (eNOS), as demonstrated by reduced phosphorylation of the Akt-428 regulated S1177 eNOS residue.³⁷ We hypothesized that the natural process of Akt induction 429 following ischemia-reperfusion is challenged by aPL and leads to inhibition of p-eNOS, as 430 described in the context of VEGF. We probed brain lysates from our model and noted 431 suppression of p-eNOS in APS-IgG MCAO animals (Figure 2I). In carotid artery specimens 432 collected from the same animals, a similar pattern of p-Akt and p-eNOS inhibition was seen in 433 the APS-IgG group while in the aorta, these molecules were inconsistently affected (Figure 434 2J, p-Akt and Figure 2K, p-eNOS).

435

436 APS-IgG enhance cell death and inhibit Akt following hypoxia-reperfusion in cultured 437 endothelial cells

438

Previous aPL-Akt associated studies focused on endothelium,^{24,37} a major aPL target.⁷ Given 439 440 the importance of endothelial BBB breakdown in stroke, in vitro endothelial models were next 441 employed to confirm our findings. Healthy HUVEC treated with APS-IgG or HC-IgG (24hr) 442 were exposed to hypoxia under nutrient restricting conditions (0.1% O_2 , 4hr) followed by 443 reperfusion and nutrient restoration. Cell death was measured in real time for up to 24hr 444 reperfusion and compared to matched cultures kept in normoxic conditions. Sensitivity of the 445 cell death assay was confirmed in HUVEC exposed to H₂O₂ (Supplementary Figure 2A) or 446 hypoxia-reperfusion (Supplementary Figure 2B). Comparison of APS-IgG vs HC-IgG treated 447 HUVEC responses revealed a non-significant trend for elevated apoptosis following 2hr 448 reperfusion (Figure 3A) and significantly elevated necrosis at all time points (Figure 3B), 449 indicating enhanced endothelial cell death in the presence of aPL.

450

We sought to establish whether aPL influence endothelial Akt in vitro, building on evidence 451 452 from our *in vivo* observations and from published aPL-endothelial studies.^{24,37} Initially, we 453 tested the same samples used to create pooled IgG for in vivo injections (n=2 APS, n=2 HC) 454 and selected phosphorylated targets were measured after 2hr reperfusion. In untreated HUVEC, both p-Akt and p-Bad were elevated following hypoxia-reperfusion compared to 455 456 normoxia (Supplementary Figure 2C-D). In APS-IgG treated HUVEC, reduced levels of p-Akt, 457 p-Bad and p-eNOS were detected under hypoxia-reperfusion and compared to HC-IgG

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

treated cells (Figure 3C). Reduced p-Akt induction in the presence of aPL, was confirmed in
an extended sample set of purified IgG (n=12 APS-IgG, n=10 HC-IgG; Table 1) used to treat
matched HUVEC cultures under hypoxia-reperfusion or normoxia (Figure 3D, Supplementary
Figure 2E). These results further highlight that aPL disrupts Akt signalling following a contextspecific insult, in this case hypoxia-reperfusion injury.

463 464

464 **APS ECFC response to hypoxia/reperfusion mimics** *in vivo* observations 465

466 Next, we employed *ex vivo* ECFC to study the impact of hypoxia-reperfusion injury on APS 467 endothelium (n=12 donors per group; Table 1). ECFC from patients with systemic disease 468 such as APS, are chronically exposed to circulating pathogenic mediators such as 469 autoantibodies and inflammatory cytokines, ultimately leading to a 'primed' phenotype that 470 persists *ex vivo*.^{31,39} Utilising APS ECFC in our study would therefore facilitate extension of 471 our *in vivo* and *in vitro* findings to a biologically relevant source of patient endothelium.

472

473 ECFC generation parameters as outlined by ECFC standardization guidelines⁴⁰ including
474 number of endothelial colonies detected, day of first colony detection and day of first passage
475 from P0 to P1 (defined as days-post PBMC seeding), were similar for APS and HC ECFC
476 (Supplementary Figure 3D) suggesting that any functional or molecular differences detected
477 were not due to initial isolation and growth capacity of patient *vs* control cells.
478

All experiments were performed in parallel matched hypoxia-reperfusion and normoxic
cultures. Mirroring the HUVEC-IgG experiments, ECFC were exposed to hypoxia and cell
death was tracked in real time for 24hr post reperfusion. Hypoxia-reperfusion promoted cell
death in both APS and HC ECFC compared to normoxic cells (Figure 4A-B, Supplementary
Figure 4A-B). Both apoptosis (Figure 4A) and necrosis (Figure 4B) were significantly more
prominent in APS-ECFC.

485

486 Dysregulation of the p-Akt response following hypoxia-reperfusion was next determined. 487 Induction of p-Akt was observed in both APS and HC ECFC following hypoxia-reperfusion and 488 compared to matched cells kept under normoxia (Supplementary Figure 4C). However, p-Akt 489 levels were robustly lower in APS-ECFC compared to HC-ECFC at both 0.5hr (early) and 2hr 490 (late) post-reperfusion, as well as under normoxic conditions (Figure 4C). Failure to activate 491 Akt resulted in the expected reduction of downstream p-Bad in APS ECFC (Figure 4D, 492 Supplementary Figure 4D). In agreement with the regulatory relationship between Akt and 493 Bad, early p-Akt correlated with late p-Bad (r=0.622, p=0.035; Supplementary Figure 4E). 494 Thus, our ex vivo findings in APS and HC ECFC recapitulated our in vivo observations and 495 the in vitro IgG-HUVEC model. 496

497 Hydroxychloroquine partially protects against hypoxia-reperfusion induced ECFC 498 death

499

500 Our group and others reported a protective effect for hydroxychloroquine (HCQ) following brain,⁴¹ heart^{42,43} and kidney⁴⁴ ischemia-reperfusion injury *in vivo* and in cellular models.^{42,44} 501 We determined whether HCQ could reverse ECFC death following hypoxia-reperfusion. Cells 502 503 were pre-treated with HCQ for 24hr followed by hypoxia-reperfusion or normoxic culture as 504 described. Under normoxic conditions, HCQ had a variable effect on apoptosis and necrosis 505 (Supplementary Figure 5A-B). Following reperfusion, HCQ suppressed apoptosis (Figure 5A) 506 and necrosis (Figure 5B) in both APS and HC ECFC but yielded a stronger protective effect 507 upon APS ECFC death.

508

509 We measured p-Akt and p-Bad levels in a small sample set (n=3 per group); p-Akt levels were 510 similar between untreated and HCQ-treated lysates (data not shown) but p-Bad levels 511 appeared to rise following HCQ treatment and hypoxia-reperfusion (Figure 5C, Supplementary

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

512 Figure 5C). Taken together, our results suggest that HCQ limits cell death during reperfusion 513 in both APS and non-APS cellular sources but its beneficial effects may be enhanced in APS.

514

515 In this study, ECFC from thrombotic APS patients with or without a previous history of 516 cardiovascular events (CVE vs no-CVE) were used. Comparison of ECFC responses from 517 these two APS subgroups showed equal susceptibility to hypoxia-reperfusion induced cell 518 death (Supplementary Figure 5D). However, in vitro treatment with HCQ conferred greater 519 protection in ECFC from no-CVE compared to CVE donors (Figure 5D). Similarly, ECFC 520 responses were compared between patients receiving HCQ compared to those not receiving 521 HCQ at the time of ECFC isolation (HCQ vs no-HCQ). No differences in the level of cell death 522 (Supplementary Figure 5E) or response to in vitro HCQ treatment was observed 523 (Supplementary Figure 5F).

524 525

526

Discussion

527 To our knowledge, we present the first in vivo model for aPL-mediated cell death following 528 ischemia-reperfusion injury and identify repression of Akt activity as a critical underlying 529 mechanism. We confirm elevated cell death and reduced p-Akt in vitro in HUVEC stimulated 530 with exogenous aPL and subjected to hypoxia-reperfusion. Excitingly, use of ex vivo APS 531 ECFC fully recapitulated our in vivo observations thus directly extending our findings to a 532 patient-relevant source of endothelium.

533

534 Stroke is the most frequent primary arterial thrombotic event in APS and the most frequent 535 recurrent thrombotic event overall (venous and arterial combined).⁴⁵⁻⁴⁷ While the relationship 536 between aPL and stroke is well-established, few studies have compared stroke severity and 537 long-term outcomes between APS and non-APS stroke patients, a particularly challenging 538 task as APS strokes occur in younger patients. A study in patients <54 years old identified a 539 correlation between aPL titres, stroke severity on admission and three-month outcomes.²⁸ 540 Another study found that cognitive impairment was more common in APS patients compared 541 to age-, gender- and cardiovascular risk factor-matched controls; within one year of follow-up, 542 progression of cognitive impairment occurred in ~21% of APS patients (13/60), 12 of whom had suffered stroke.²⁹ Higher risk of haemorrhagic transformation post APS-associated stroke 543 544 regardless of thrombolytic therapy was also reported; APS patients spent longer periods in 545 hospital and had a greater risk of mortality despite being significantly younger compared to 546 non-APS stroke patients.³⁰

547

548 Here, we investigated the impact of aPL in a vascular event setting such as stroke, focusing 549 on the critical period following clot dissolution and brain reperfusion by employing a non-550 thrombotic outcome. Our study highlights an additional pathogenic effect of aPL that goes 551 beyond lowering the threshold for arterial thrombosis and describes a mechanism for 552 enhanced tissue injury during the reperfusion phase, which may account for the worse 553 prognosis proposed in APS-associated stroke. Patients may benefit from close monitoring, 554 particularly if thrombolysis is given, and incorporating readouts for disability and cognitive 555 impairment during long-term follow up.

556

557 We propose that aPL, free to enter the brain following BBB breakdown, impact Akt-mediated 558 homeostatic mechanisms critical to cell survival during reperfusion. Analysis of limited material 559 from our *in vivo* model may indicate a role for the tumour suppressor PTEN in aPL-mediated 560 Akt inhibition. This was a surprising finding as PTEN acts upstream of Akt to prevent activation 561 of phosphoinositide 3-kinase (PI3K)-Akt signalling and may indicate the presence of an 562 inhibitory complex composed of Akt, PTEN and other PI3K signalling components recruited to 563 sites near the plasma membrane.

564

565 Another unexpected finding was that, following stroke, renal p-Akt levels were elevated in 566 APS-IgG compared to HC-IgG animals, an observation that agrees with an elegant study for

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

APS nephropathy.²⁴ In the absence of stroke, p-Akt levels did not differ between APS-IgG and 567 HC-IgG kidney or brain. We speculate that, similar to the 'two-hit' model for thrombotic APS, 568 569 the presence of circulating aPL combined with the haemodynamic impact of MCA occlusion 570 influences the renal system in our model and drives renal Akt activation. 571

Both the APS nephropathy study and a second in vivo thrombosis model study implicate 572 573 dysregulation of Akt and its signalling mediators in endothelium, but in opposing ways -574 suggesting activation²⁴ and inhibition³⁷ respectively. A key difference between these two 575 studies was the use of exogenous VEGF (a potent Akt inducer) in the latter,³⁷ suggesting that 576 aPL may prevent Akt activation following biomechanical challenge. Harnessing this information, we sought to understand the premise of aPL-mediated Akt dysregulation in the 577 578 presence of an Akt-activating stimulus such as hypoxia-reperfusion. We focused on 579 endothelium, initially showing reduced p-eNOS levels (a downstream Akt target) in brain and 580 carotid artery specimens from APS-IgG animals. A series of in vitro experiments corroborated 581 our in vivo findings, whereby aPL repressed Akt activation following in vitro hypoxia-582 reperfusion. We utilized two sources of endothelial cells: HUVEC treated with APS-IgG (the 583 most common in vitro model for aPL-endothelial studies) and ECFC isolated from patients. 584

585 ECFC, considered to originate from true circulating endothelial 'progenitors', are capable of clonal expansion and vascular repair, and appear to be 'biologically primed' even after long 586 587 term in vitro culture. This precious source of patient endothelium has offered mechanistic 588 insight into endothelial dysfunction across a range of diseases,³¹ including rheumatoid arthritis 589 where ECFC were shown to be hyperproliferative, proangiogenic and sensitized to TNFa 590 stimulation.³⁹ Here, we utilise APS ECFC for the first time to demonstrate that both functional 591 (cell death) and molecular (Akt) outcomes are negatively impacted under hypoxia-reperfusion, 592 mirroring our in vivo observations and underlining the utility of ECFC for the exploration of 593 endothelial dysfunction in APS. 594

595 Our study has some limitations. Our model follows a standard approach of passive transfer of 596 aPL in vivo to study APS pathogenesis ('acute' APS models). 'Chronic' APS models involving 597 immunisation with cardiolipin or B2GPI, are less common but mimic observations from acute 598 models. We used a small number of animals for our *in vivo* model and a moderate number of 599 patients (purified IgG and ECFC) to confirm our findings. In vivo experiments employed pooled 600 IgG isolated from two APS and four HC donors. For comparison, our previous studies^{9,13,21} and those by other groups^{11,12,48} also tested a small number of individual APS-IgG or HC-IgG 601 602 samples in animal models, ranging from 1-6 samples per group. We previously used pooled 603 HC-IgG in vivo^{9,13} and pooled APS-IgG and HC-IgG in vitro with downstream individual sample 604 validation.^{22,49} Another limitation is that we did not explore reversal of the Akt response with 605 commercially available pan-Akt activators as they are unlikely to be employed in real world 606 clinical practice. 607

608 Despite these limitations, we demonstrate consistency across our findings and present novel 609 in vivo and ex vivo ECFC-based models for oxygen deprivation-reperfusion injury in APS. 610 Future work will aim to establish how aPL-mediated functional and molecular disturbances 611 can be therapeutically reversed. We previously reported on the pro-survival effect of HCQ in 612 an *in vivo* cardiac ischemia-reperfusion model and in cardiomyocytes *in vitro*.⁴² This effect was 613 mediated by ERK and not Akt, but serves as an example of repurposing or reconsidering the 614 benefits of pre-existing drugs already used in autoimmune disease management. Here, using 615 blood-derived ECFC we provide proof-of-principle that HCQ may offer protection against cell 616 death following hypoxia-reperfusion, an effect that is more pronounced in APS compared to 617 HC ECFC. Incorporating HCQ as an adjunct immunomodulatory treatment in APS 618 management is increasingly implemented, and may provide similar benefits to those seen in 619 systemic lupus erythematosus and rheumatoid arthritis where HCQ is proposed to reduce 620 cardiovascular risk.50

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

In conclusion, we translate biological evidence generated from a novel *in vivo* APS stroke model to *in vitro* studies with aPL-treated HUVEC and finally, to APS-derived *ex vivo* EC. We identify an intervenable pathobiological process independent of thrombosis that may inform clinical management of patients with aPL and stroke. Further research is required to establish whether aPL-mediated Akt disturbances can be manipulated therapeutically and the efficacy of immunomodulation towards thrombotic and non-thrombotic pathogenesis in APS.

628 Acknowledgments

This manuscript is dedicated to Professor Justin Mason (Imperial College London) and Professor Silvia Pierangeli (University of Texas Medical Branch) who passed away prematurely. We are sincerely grateful to Mrs Valerie Taylor (University College London) for sharing her expertise and supporting the *in vivo* part of this study. Infrastructure support for this research was provided by the NIHR Imperial Biomedical Research Centre (BRC).

634

627

635 Sources of Funding

636 C.P is supported by Versus Arthritis (21223) and the Imperial College-Wellcome Trust
637 Institutional Strategic Support Fund. D.J.S. was supported by British Heart Foundation
638 Intermediate and Senior Basic Science Research Fellowships (FS/15/33/31608,
639 FS/SBSRF/21/31020), the BHF Centre for Regenerative Medicine (RM/17/1/33377), the MRC
640 (MR/R026416/1) and the Wellcome Trust (212937/Z/18/Z). D.J.A is funded by the MRC
641 (MR/V037633/1). This work was partly funded by the Rosetrees Trust (C.P, I.P.G).

642

643 Disclosures

- 644 C.P, A.R, I.P.G and Y.I are co-inventors on a novel drug for APS (US20160287718A). There 645 are no other relevant disclosures.
- 646

647 <u>References</u>

- 648 1. Collaborators GBDS. Global, regional, and national burden of stroke, 1990-2016: a 649 systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 650 2019;18(5):439-58.
- 651 2. Sciascia S, Sanna G, Khamashta MA, et al. The estimated frequency of antiphospholipid
 652 antibodies in young adults with cerebrovascular events: a systematic review. *Ann Rheum Dis*653 2015;74(11):2028-33.
- 654 3. George MG. Risk Factors for Ischemic Stroke in Younger Adults: A Focused Update. *Stroke* 655 2020;51(3):729-35.
- 656 4. Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome 657 classification criteria. *Ann Rheum Dis* 2023;82(10):1258-70.
- 5. Pezzini A, Grassi M, Lodigiani C, et al. Predictors of long-term recurrent vascular events
 after ischemic stroke at young age: the Italian Project on Stroke in Young Adults. *Circulation*2014;129(16):1668-76.
- 661 6. Muller-Calleja N, Kohler A, Siebald B, et al. Cofactor-independent antiphospholipid
 662 antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications
 663 for the antiphospholipid syndrome. *Thromb Haemost* 2015;113(5):1071-83.
- 664 7. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: 665 understanding the antibodies. *Nat Rev Rheumatol* 2011;7(6):330-9.
- 8. Pierangeli SS, Liu SW, Anderson G, Barker JH, Harris EN. Thrombogenic properties of
 murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human
 immunoglobulin G antiphospholipid antibodies. *Circulation* 1996;94(7):1746-51.
- 9. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN.
 Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells
 in vitro and in vivo. *Circulation* 1999;99(15):1997-2002.
- 672 10. Jankowski M, Vreys I, Wittevrongel C, et al. Thrombogenicity of beta 2-glycoprotein I-
- 673 dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the
- 674 hamster. *Blood* 2003;101(1):157-62.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

675 11. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-676 glycoprotein I is complement dependent and requires a priming factor. Blood 677 2005;106(7):2340-6.

678 12. Arad A, Proulle V, Furie RA, Furie BC, Furie B. beta(2)-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation 679 680 in a mouse model. Blood 2011;117(12):3453-9.

681 13. Pericleous C, Ruiz-Limon P, Romay-Penabad Z, et al. Proof-of-concept study 682 demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of 683 beta2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. 684 Rheumatology (Oxford) 2015;54(4):722-7.

- 685 14. Meng H, Yalavarthi S, Kanthi Y, et al. In Vivo Role of Neutrophil Extracellular Traps in 686 Antiphospholipid Antibody-Mediated Venous Thrombosis. Arthritis Rheumatol 687 2017:69(3):655-67.
- 688 15. Armstrong SC. Protein kinase activation and myocardial ischemia/reperfusion injury. 689 Cardiovasc Res 2004;61(3):427-36.
- 690 16. Zhao H, Sapolsky RM, Steinberg GK. Phosphoinositide-3-kinase/akt survival signal 691 pathways are implicated in neuronal survival after stroke. Mol Neurobiol 2006;34(3):249-70.
- 692 17. Sun J, Nan G. The Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway as a 693 Discovery Target in Stroke. J Mol Neurosci 2016;59(1):90-8.
- 694 18. Aronovich R, Gurwitz D, Kloog Y, Chapman J. Antiphospholipid antibodies, thrombin and 695 LPS activate brain endothelial cells and Ras-dependent pathways through distinct 696 mechanisms. Immunobiology 2005;210(10):781-8.
- 697 19. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement 698 of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid 699 antibodies. Arthritis Rheum 2005;52(5):1545-54.
- 700 20. Lopez-Pedrera C, Buendia P, Cuadrado MJ, et al. Antiphospholipid antibodies from 701 patients with the antiphospholipid syndrome induce monocyte tissue factor expression through 702 the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein 703 kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006;54(1):301-11.
- 704 21. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z, et al. Role of p38 mitogen-activated 705 protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell 706 activation. J Thromb Haemost 2007;5(9):1828-34.
- 707 22. Lambrianides A, Carroll CJ, Pierangeli SS, et al. Effects of polyclonal IgG derived from 708 patients with different clinical types of the antiphospholipid syndrome on monocyte signaling 709 pathways. J Immunol 2010;184(12):6622-8.
- 710 23. Zhou H, Chen D, Xie H, et al. Activation of MAPKs in the anti-beta2GPI/beta2GPI-induced 711 tissue factor expression through TLR4/IRAKs pathway in THP-1 cells. Thromb Res 712 2012;130(4):e229-35.
- 713 24. Canaud G, Bienaime F, Tabarin F, et al. Inhibition of the mTORC pathway in the 714 antiphospholipid syndrome. N Engl J Med 2014;371(4):303-12.
- 715 25. Bourke LT, McDonnell T, McCormick J, et al. Antiphospholipid antibodies enhance rat
- 716 neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 717 MAPK. Cell Death Dis 2017;8(1):e2549.
- 718 26. Agostinis C, Biffi S, Garrovo C, et al. In vivo distribution of beta2 glycoprotein I under 719 various pathophysiologic conditions. *Blood* 2011;118(15):4231-8.
- 720 27. Grossi C, Artusi C, Meroni P, et al. beta2 glycoprotein I participates in phagocytosis of 721 apoptotic neurons and in vascular injury in experimental brain stroke. J Cereb Blood Flow 722 Metab 2021;41(8):2038-53.
- 723 28. Rodriguez-Sanz A, Martinez-Sanchez P, Prefasi D, et al. Antiphospholipid antibodies
- 724 correlate with stroke severity and outcome in patients with antiphospholipid syndrome. 725 Autoimmunity 2015;48(5):275-81.
- 726 29. Medina G, Cime-Ake E, Bonilla-Vazquez R, et al. Disability and cognitive impairment are
- 727 interdependent in primary antiphospholipid syndrome. Lupus 2022;31(9):1104-13.

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

- 30. Mehta T, Hussain M, Sheth K, Ding Y, McCullough LD. Risk of hemorrhagic transformation
 after ischemic stroke in patients with antiphospholipid antibody syndrome. *Neurol Res*2017;39(6):477-83.
- 731 31. Paschalaki KE, Randi AM. Recent Advances in Endothelial Colony Forming Cells Toward
 732 Their Use in Clinical Translation. *Front Med (Lausanne)* 2018;5:295.
- 32. Giles I, Pericleous C, Liu X, et al. Thrombin binding predicts the effects of sequence
 changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. J *Immunol* 2009;182(8):4836-43.
- 736 33. Pericleous C, Ferreira I, Borghi O, et al. Measuring IgA Anti-beta2-Glycoprotein I and
 737 IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the
 738 Antiphospholipid Syndrome. *PLoS One* 2016;11(6):e0156407.
- 34. Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the Scientific and
 Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the
 International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus
 anticoagulant detection and interpretation. *J Thromb Haemost* 2020;18(11):2828-39.
- 35. Badin RA, Modo M, Cheetham M, et al. Protective effect of post-ischaemic viral delivery
 of heat shock proteins in vivo. *J Cereb Blood Flow Metab* 2009;29(2):254-63.
- 745 36. Panizzo RA, Gadian DG, Sowden JC, Wells JA, Lythgoe MF, Ferretti P. Monitoring
 746 ferumoxide-labelled neural progenitor cells and lesion evolution by magnetic resonance
 747 imaging in a model of cell transplantation in cerebral ischaemia. *F1000Res* 2013;2:252.
- 37. Sacharidou A, Chambliss KL, Ulrich V, et al. Antiphospholipid antibodies induce
 thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium. *Blood* 2018;131(19):2097-110.
- 38. Li W, Huang R, Chen Z, Yan LJ, Simpkins JW, Yang SH. PTEN degradation after ischemic
 stroke: a double-edged sword. *Neuroscience* 2014;274:153-61.
- 39. Leblond A, Pezet S, Cauvet A, et al. Implication of the deacetylase sirtuin-1 on synovial
 angiogenesis and persistence of experimental arthritis. *Ann Rheum Dis* 2020;79(7):891-900.
- 40. Smadja DM, Melero-Martin JM, Eikenboom J, Bowman M, Sabatier F, Randi AM.
 Standardization of methods to quantify and culture endothelial colony-forming cells derived
 from peripheral blood: Position paper from the International Society on Thrombosis and
 Haemostasis SSC. *J Thromb Haemost* 2019;17(7):1190-94.
- 41. Babataheri S, Malekinejad H, Mosarrezaii A, Soraya H. Pre-treatment or post-treatment
 with hydroxychloroquine demonstrates neuroprotective effects in cerebral
 ischemia/reperfusion. *Fundam Clin Pharmacol* 2022
- 42. Bourke L, McCormick J, Taylor V, et al. Hydroxychloroquine Protects against Cardiac
 Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation. *PLoS*One 2015;10(12):e0143771.
- 43. Marsh KM, Rastogi R, Zhang A, Wu D, Kron IL, Yang Z. Hydroxychloroquine Attenuates
- Myocardial Ischemic and Post-Ischemic Reperfusion Injury by Inhibiting the Toll-Like Receptor
 9 Type I Interferon Pathway. *Cardiol Cardiovasc Med* 2022;6(4):416-23.
- 44. Tang TT, Lv LL, Pan MM, et al. Hydroxychloroquine attenuates renal ischemia/reperfusion
 injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. *Cell Death Dis*2018;9(3):351.
- 45. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic
 manifestations and patterns of disease expression in a cohort of 1,000 patients. *Arthritis Rheum* 2002;46(4):1019-27.
- 46. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the
 antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000
 patients. *Ann Rheum Dis* 2009;68(9):1428-32.
- 47. Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid
- syndrome during a 10-year period: a multicentre prospective study of 1000 patients. *Ann Rheum Dis* 2015;74(6):1011-8.
- 780 48. Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B. Platelets are required for
- enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.
- 782 *Blood* 2014;124(4):611-22.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

783 49. Ripoll VM, Lambrianides A, Pierangeli SS, et al. Changes in regulation of human monocyte 784 proteins in response to IgG from patients with antiphospholipid syndrome. Blood 785 2014;124(25):3808-16.

786 50. Arachchillage DJ, Laffan M, Pericleous C. Hydroxychloroquine as an Immunomodulatory

787 and Antithrombotic Treatment in Antiphospholipid Syndrome. Int J Mol Sci 2023;24(2)

788

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

789 **Tables**

790

791 Table 1: Demographics and clinical characteristics of sampled cohort.

	IgG-in vivo		IgG-HUVEC		ECFC	
	APS	HC	APS	HC	APS	HC
	(n=2)	(n=4)	(n=14)	(n=12)	(n=12)	(n=12)
Age, yrs	35.5	30.5	51.0	45.5	59	41.5
[Median (Range)]	(34-37)	(29-37)	(34-68)	(29-61)	(25-81)	(28-61)
Female	2	4	10 (71%)	10 (83%)	8 (67%)	8 (67%)
	(100%)	(100%)				
Ethnicity*	2W	4W	12W, 1A,	12W	8W, 1A,	10W, 1A,
			10		1Ar, 10	1B
Clinical history [†] (%)						
Transient ischemic attack	-		1 (7%)		3 (25%)	
Stroke	1 (50%)		10 (71%)		6 (50%)	
Myocardial Infarction	-		2 (14%)		1 (8%)	
Other Arterial	-		2 (14%)		3 (25%)	
Thrombosis						
Deep Vein	-		3 (21%)		4 (33%)	
Thrombosis						
Pulmonary	-		2 (14%)		2 (17%)	
Embolism						
Other Venous	-		1 (7%)		3 (25%)	
Thrombosis			- (()			
Pregnancy	1 (50%)		3 (30%)		1 (13%)	
morbidity+	4 (500()		4 (70()			
Catastrophic APS	1 (50%)		1 (7%)		-	
Thrombocytopenia	-		1 (7%)		1 (8%)	
SLE-APS [®]	1 (50%)		3 (21%)		-	
aPL serology (%)						
Lupus anticoagulant	2 (100%)		11 (79%)		10 (83%)	
IgG anticardiolipin#	2 (100%)		13 (93%)		7 (58%)	
IgG anti-β2GPI#	2 (100%)		10 (71%)		7 (58%)	
Triple positive	2		11 (79%)		5 (42%)	
	(100%)		11 (7370)		J (+270)	
Treatment (%)						
Warfarin	2 (100%)		12 (86%)		10 (83%)	
Anti-platelet	-		5 (36%)		8 (67%)	
(including aspirin)					_ / / `	
Hydroxychloroquine	-		6 (43%)		7 (58%)	
ACEi/ARBs, Ca ²⁺ /beta-blockers**	-		4 (29%)		7 (58%)	
Statins	-		2 (14%)		6 (50%)	

792 * W, White; A, Asian; Ar, Arab; B, Black; O, any other ethnic group

793 † Multiple events for some patients

794 [‡]Percentage of female patients with pregnancy morbidity

795 SLE, systemic lupus erythematosus (secondary APS). No incidence of other rheumatic 796 diseases.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

- 797 #aPL titres >20GPLU for IgG anti-cardiolipin, >8GBU for IgG anti- β_2 GPI tested in-house
- **ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; 798
- 799 Ca2+, calcium channel blockers
- 800

Supplementary Table 1. List of antibodies. 801

	Target Species	Host	Dilution	Supplier	Catalogue					
					number					
Immunoblot, primary antibody										
Cleaved	Human/Rodent	Rabbit	1:1000	Cell Signaling						
caspase 3				Technology						
				(CST)						
p-Akt S473	Human/Rodent	Rabbit	1:1000	CST	4070					
p-Akt T308	Human/Rodent	Rabbit	1:1000	CST	13038					
p-Bad S136	Human/Rodent	Rabbit	1:1000	CST	4366/5286					
p-eNOS S1177	Human/Bovine/Pig	Rabbit	1:1000	CST	9571					
p-S6RP	Human/Rodent	Rabbit	1:5000	CST	4858					
Akt	Human/Rodent	Rabbit	1:5000	CST	4685					
Akt	Human/Rodent	Mouse	1:5000	CST	2920					
β-actin	Human/Rodent	Mouse	1:10000	CST	3700					
Bad	Human/Rodent	Rabbit	1:1000	CST	9292					
GAPDH	Human/Rodent	Rabbit	1:10000	CST	2118					
PP2AC	Human/Rodent	Rabbit	1:1000	CST	2038					
PTEN	Human/Rodent	Rabbit	1:1000	CST	9188					
np-PTEN	Human/Rodent	Rabbit	1:1000	CST	7960					
S6RP	Human/Rodent	Rabbit	1:5000	CST	2217					
vinculin	Human/Rodent	Rabbit	1.10000	CST	13901					
Immunonrecipitation canture antibody										
Akt	Human	Rabbit	1:40	CST	4685					
Immunoblot, secondary/detection antibody										
Anti-rabbit IgG.	Rabbit	Swine	1:5000	Dako	P039901					
horseradish										
peroxidase										
Anti-mouse laG.	Mouse	Goat	1:5000	Dako	P044701					
horseradish										
peroxidase										
Anti-rabbit IgG,	Rabbit	Goat	1:5000	ThermoFisher	SA5-35571					
DyLight™ 800-										
4x PEG										
Anti-mouse laG.	Mouse	Goat	1:10000	ThermoFisher	A32729					
AF680										
Anti-rabbit IgG,	Rabbit	Mouse	1:2000	CST	5127					
conformation										
specific										
ECFC purity, flow cytometry										
CD144 PE	Human	Mouse	10µL	EBioscience	12-1449-82					
CD146 BV421	Human	Mouse	5µL	Biolegend	361004					
CD31 FITC	Human	Mouse	5µL	Biolegend	303104					
CD45 BV510	Human	Mouse	5µL	Biolegend	368526					
CD14 APC	Human	Mouse	5µL	Biolegend	301808					
Zombie NIR™	-	-	1:375	Biolegend	423106					
Fixable Viabilitv			_	J						
Dve										

802

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

803 Figure Legends

804

805 Figure 1. aPL enhance brain injury following ischemia-reperfusion in vivo. Rats injected 806 with 1mg human IgG were subjected to transient middle cerebral artery occlusion (MCAO) 807 followed by reperfusion (n=5-8 APS-IgG; n=5-6 HC-IgG). An additional litter of rats were 808 injected with APS-IgG or HC-IgG but not subjected to MCAO (no-MCAO, n=6 per group). (A) 809 MCAO was performed for 1hr and reperfusion for 24hr (n=8 APS-lgG; n=6 HC-lgG). A total of 810 3/8 APS mice died before endpoint (2/3 with completed histology are marked as red 811 diamonds). Analysis was performed after excluding animals that died pre-endpoint. (B) MCAO 812 was reduced to 0.5hr followed by reperfusion for 24hr (n=5 per group). Rats administered 813 APS-IgG had significantly larger infarcts at endpoint. (C) Example image of brain slices 814 stained with tetrazolium chloride (TTC) to discriminate between metabolically active (red) and 815 dead tissue (white). (D-E) Higher levels of human IgG were detected in (D) brain lysates and 816 (E) serum from MCAO compared to no-MCAO littermates. (F) Fifteen minutes post IgG 817 injection and prior to MCAO, rat serum was sampled for IgG aPL activity. Both aCL and anti-818 B2GPI were detected. (G-H) At endpoint. APS-IgG MCAO rat sera were (G) aCL and (H) anti-819 β2GPI positive. aCL were also detected in APS-IgG no-MCAO littermates. aPL were 820 undetectable in HC-IgG rats. (I) Activation/cleavage of caspase-3 was evident in MCAO brain 821 tissue and was higher in the APS-IgG group (n=3 per group). Normalised to GAPDH. *p<0.05; 822 **p<0.01; ***p<0.001; ****p<0.0001; *ns*, non-significant. 823

824 Figure 2. aPL dysregulate the pro-survival kinase Akt. (A) Following ischemia-reperfusion 825 injury, HC-IgG animals demonstrated increased phosphorylation of Akt (p-Akt S473) in the 826 brain. In comparison, p-Akt was lower in APS-IgG animals (n=4 MCAO, n=6 no-MCAO per 827 IgG group). (B-E) Levels of natural Akt inhibitors PP2A(C, catalytic subunit), PTEN and active 828 PTEN (non-phosphorylated, np-PTEN) were unaltered in the two MCAO groups. Whole 829 lysates (B, left panel) or Akt-immunoprecipitated lysates (B, right panel) were blotted for (C) 830 PP2AC, (D) PTEN and (E) np-PTEN demonstrating that Akt is bound to active PTEN 831 exclusively in the APS group (n=2 per group). (F-G) Analysis of downstream Akt signalling in 832 MCAO brain revealed lower levels of (F) p-Bad S136 and (G) p-S6RP S235/6 in the APS 833 group. (H) Higher p-Akt levels were detected in matched MCAO kidney lysates from APS-IgG 834 compared to HC-IgG animals. (I) Additional Akt signalling analysis identified lower p-eNOS 835 S1177 levels in brain lysates of APS-IgG compared to HC-IgG animals (n=4 per group). (J) p-836 Akt and (K) p-eNOS were lower in APS-IgG carotid artery but not aortic lysates (n=3 per 837 group). For panels A, H representative blots are shown for n=3 animals per MCAO and no-838 MCAO conditions. Complete blots for all individual lysates tested are provided in 839 Supplementary Figure 1C (brain) and 1G (kidney). Results are normalised as follows: p-Akt, 840 p-Bad, p-S6 to total Akt, Bad, S6 respectively; PP2AC, PTEN, np-PTEN to co-841 immunoprecipitated total Akt; p-eNOS to vinculin. *p<0.05; **p<0.01; ***p<0.001; 842 ****p<0.0001; ns, non-significant.

843

844 Figure 3. aPL promote endothelial cell death and repress Akt activation following 845 hypoxia-reperfusion injury in vitro. HUVEC were incubated with 100µg/mL human lgG for 846 4hr under hypoxic conditions followed by reperfusion for up to 24hr. Matched cells were 847 treated with IgG and kept under normoxic conditions. (A-B) Cell death is expressed as fold 848 change between 2hr, 3hr and 24hr reperfusion vs matched normoxic cultures. Higher rates of 849 (A) apoptosis and (B) necrosis were observed in APS-IgG compared to HC-IgG treated 850 HUVEC following hypoxia-reperfusion (n=7 per group). (C) After 2hr reperfusion, cells were 851 harvested for protein analysis. Treatment with APS-IgG resulted in lower p-Akt S473, p-Bad 852 S136 and p-eNOS S1177 levels compared to HC-IgG (n=2 per group). Results are normalised 853 to loading controls: p-Akt/p-Bad to β -actin and p-eNOS to vinculin. (D) Extended IgG 854 experiments revealed reduction of p-Akt following reperfusion. Representative immunoblots 855 for two APS-IgG and two HC-IgG treated cultures under hypoxia-reperfusion (R) or normoxia 856 (N), and untreated cells (media alone, M). Immunoblots for the remaining IgG samples tested

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

857 are provided in Supplementary Figure 2E. Results are shown as fold change of p-Akt levels 858 (normalised to β -actin) at 2hr reperfusion *vs* normoxia (n=12 APS-IgG, n=10 HC-IgG). 859 *p<0.05; **p<0.01; ****p<0.001; ns, non-significant. 860

861 Figure 4. Exacerbated cell death and reduced p-Akt in APS ECFC following hypoxia-862 reperfusion. Primary ECFC were subjected to hypoxia-reperfusion or normoxia. (A-B) Cell 863 death is expressed as fold change between 2hr, 3hr and 24hr reperfusion vs matched 864 normoxic cultures. Higher rates of (A) apoptosis and (B) necrosis were observed in APS 865 compared to HC ECFC following hypoxia-reperfusion (n=10 per group). Luminescence 866 (apoptosis) and fluorescence (necrosis) traces are provided in Supplementary Figure 4A-B. 867 (C) Following 0.5hr and 2hr reperfusion, p-Akt levels were lower in APS (n=7) compared to 868 HC ECFC (n=5). Left panel shows p-Akt normalised to β -actin for 0.5hr, 2hr reperfusion (0.5R, 869 2R) and normoxia (N). Right panel shows fold change of normalised p-Akt between culture 870 conditions. (D) Similarly, p-Bad levels were lower in APS compared to HC ECFC. Comparative 871 responses in two untreated HUVEC pools (HUV1, HUV2) are shown for both p-Akt (C) and p-872 Bad (D); see quantification in Supplementary Figures C-D. Yellow circles, HC; blue circles, APS (n=10 per group). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns, non-significant. 873

874

888

875 Figure 5. HCQ protects against hypoxia-reperfusion ECFC death in vitro. (A-B) ECFC 876 were pre-treated with 10µg/mL hydroxychloroquine (HCQ) for 24hr followed by hypoxia-877 reperfusion or kept under normoxic conditions. Cell death is expressed as fold change 878 between HCQ-treated and untreated cultures. At 2hr and 3hr post reperfusion, HCQ 879 suppressed (A) apoptosis and (B) necrosis in APS and a proportion of HC ECFC. This 880 protective effect was more prominent in APS ECFC (n=10 per group). (C) HCQ promotes 881 elevated p-Bad levels post-reperfusion in both HC and APS ECFC (n=3 per group). (D) 882 Separating APS ECFC donors into those with previous cardiovascular events (CVE, n=6) vs 883 those without (no-CVE, n=4) revealed greater protection from hypoxia-reperfusion induced cell death in the no-CVE group. Results are expressed as fold change of cell death in HCQ-884 885 treated vs untreated ECFC. In the absence of HCQ treatment, no obvious difference between 886 cell death rates was observed in CVE vs no-CVE groups (Supplementary Figure 5E). *p<0.05; 887 **p<0.01; ***p<0.001; ****p<0.0001; *ns*, non-significant.

889 Supplementary Figure 1:

(A) Purified APS- and HC-IgG used in the in vivo model was tested for aCL and ab2GPI activity
 at up to 500ug/mL. ELISA results are shown as net optical density units (OD450nm). Using
 in-house calibrators with pre-defined activity units,³³ both APS-IgG preparations were strongly
 positive (activity units provided for 100ug/mL). HC-IgG were negative (n=2 APS, n=4 HC).

- 894 (B) Schematic of APS *in vivo* stroke model procedures.
- 895 (C) p-Akt S473 blots for individual brain lysates (n=4 per MCAO group, n=6 per no-MCAO group). Normalised to total Akt. Quantification is shown in Figure 2A.
- (D) p-Akt T308 levels in MCAO rat brain revealed lower levels in APS compared to HC animals
 (n=4 per group). Normalised to total Akt. Results are shown as median ± interquartile range.
 (E) p Akt levels pagetively correlate with inferent size (n=4 per group). *p <0.05
- **(E)** p-Akt levels negatively correlate with infarct size (n=4 per group). *p<0.05.
- 900 (F) p38, ERK1/2 (p44/p42) and JNK1/2 (p54/p46) in MCAO rat brain were similar in APS and
 901 HC animals (n=4 per group). Normalised to total p38, ERK1/2, JNK1/2 respectively. Results
 902 are shown as median ± interquartile range.
- 903 **(G)** p-Akt S473 blots for individual kidney lysates (n=5 per APS MCAO, n=4 HC MCAO, n=6 904 APS and HC no-MCAO). Normalised to total Akt. Quantification is shown in Figure 2H.
- 905 (H) p-Akt S473 was assessed in the liver and spleen of MCAO animals with no apparent
 906 differences observed (all n=5 except HC spleen, n=4). Normalised to total Akt. Results are
 907 shown as median ± interquartile range.
- 908

909 **Supplementary Figure 2**:

910 (A) As a positive control for the real-time apoptosis/necrosis assay, HUVEC under normoxic

All rights reserved. No reuse allowed without permission.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

- 912 induced both necrosis and apoptosis. Results are shown at 2hr, 3hr and 24hr post- H_2O_2 913 removal and expressed as fold change of apoptosis/necrosis between H_2O_2 and untreated 914 HUVEC (n=2 individual HUVEC pools).
- (B) Enhanced cell death in HUVEC subjected to simulated hypoxia-reperfusion *in vitro*, shown
 at 2hr, 3hr and 24hr post reperfusion. Results are expressed as fold change of
 apoptosis/necrosis between matched reperfused and normoxic cultures.
- 918 (C) Levels of p-Akt in HUVEC tested at 0.5hr, 2hr reperfusion (0.5R, 2R) and normoxia (N). p-919 Akt is higher following hypoxia/reperfusion compared to normoxia. Normalised to β -actin.
- 920 (D) Levels of p-Bad in HUVEC tested at 0.5hr, 2hr reperfusion (0.5R, 2R) and normoxia (N).
- 921 p-Bad is higher following hypoxia-reperfusion compared to normoxia. Normalised to β -actin.
- 922 (E) p-Akt S473 and β -actin blots for individual APS-IgG and HC-IgG treated HUVEC cultures
- 923 (n=10 APS-IgG, n=8 HC-IgG shown here). M=media alone, untreated. Lysates were collected
 924 at 2hr reperfusion (R) or under normoxia (N). Blots from two additional IgG samples per group
 925 and total quantification is shown in Figure 3D.
- 926

927 Supplementary Figure 3:

- (A) Schematic of ECFC isolation. PBMC are plated on collagen coated cell culture vessels
 and grown in endothelial growth medium-2 (EGM2) supplemented with 20% FBS. Endothelial
 colonies usually appear within 7-21 days post PBMC seeding and passaged further once well
 established.
- (B) (i) ECFC colony detected at day 10 post PBMC isolation (left image) and (ii) established
 ECFC at passage 4 (4x magnification). Representative immunofluorescence images of ECFC
- at passage 4, stained for canonical endothelial markers (iii) CD144; (iv) von Willebrand factor
 (vWF); and (v) CD31.
- 936 (C) Flow cytometry gating strategy to characterize endothelial identity of ECFC at passage 4.
- (i) Forward/side scatter (FS/SS) gating on all cells. (ii) Doublets are excluded to capture only
 single cells. (iii) Dead cells stained with Zombie dye are excluded. (iv-v) ECFC are
 CD31/CD144/CD146 positive and (vi) CD45/CD14 negative.
- 940 (D) ECFC generation parameters as recommended by international standardisation
 941 guidelines for ECFC isolation.⁴⁰ (i) Colony count: total number of colonies detected,
 942 normalised to number of PBMC seeded (x10⁷). (ii) First colony detected: expressed in number
 943 of days post PBMC seeding. (iii) First passage: number of days post PBMC seeding where
 944 ECFC colonies were passaged from P0 to P1. Results are shown as median ± interquartile
 945 range. No significant differences were found.
- 946

947 **Supplementary Figure 4**:

- 948 (A-B) Representative (A) luminescence (apoptosis) and (B) fluorescence (necrosis) traces for
 949 APS and HC ECFC measured at 2hr, 3hr and 24hr reperfusion or normoxia (n=5 per group).
 950 The average of n=3 replicate wells per sample per condition is plotted.
- 951 **(C)** Levels of p-Akt in (i) HC ECFC and (ii) APS ECFC tested at 0.5hr, 2hr reperfusion (0.5R, 952 2R) and normoxia (N). Normalised to β -actin. *p<0.05; *ns*, non-significant.
- (D) Levels of p-Bad in (i) HC ECFC and (ii) APS ECFC tested at 0.5hr, 2hr reperfusion (0.5R, 2B) and normatic (N). Normalized to 0 actin. *p <0.05; no. non significant.
- 954 2R) and normoxia (N). Normalised to β-actin. *p<0.05; *ns*, non-significant.
- 955 **(E)** p-Akt levels at 0.5hr (x-axis) correlate with p-Bad levels at 2hr reperfusion (y-axis). 956

957 **Supplementary Figure 5**:

- (A-B) Variable efffect of hydroxychloroquine (HCQ) on (A) apoptosis and (B) necrosis in ECFC
 cultured under normoxic conditions.
- 960 (C) p-Bad levels in HC and APS ECFC with or without HCQ treatment under (i) normoxia and961 following (ii) 0.5hr or (iii) 2hr reperfusion.
- 962 **(D)** Comparison of cell death responses in ECFC from APS donors with a previous history of cardiovascular events (CVE) *vs* those without (no-CVE).
- 964 **(E)** Comparison of cell death responses in ECFC from APS donors who received HCQ 965 compared to those not receiving HCQ at the time of ECFC isolation.

Pericleous et al: Antiphospholipid antibodies in reperfusion injury

966 (F) Comparison of cell death responses following exogenous HCQ treatment, between ECFC 967 from APS donors who were on HCQ compared to those not on HCQ at the time of ECFC 968 isolation. (D-F) are expressed as fold change of cell death rates under hypoxia-reperfusion 969 (H/R) vs normoxia.































Figure 5



(D)

HCQ-treated ECFC: no-CVE vs CVE response to hypoxia/reperfusion





p38

Erk p42

Erk p44

Jnk p46

Jnk p52



Supplementary Figure 2



Supplementary Figure 3





29



Supplementary Figure 5

0.0

2 3 24 2 3

Time (hours)

post reperfusion



Cytoprotective

1 24

3 24

2 3

Necrosis

2

24

Apoptosis